Cancer drug resistance is an enormous problem. It is responsible for most relapses in
cancer patients following apparent remission after successful therapy. Understanding …

Cancer is a genetic disease originating from the accumulation of gene mutations in a
cellular subpopulation. Although many therapeutic approaches have been developed to …

To date, over 100 small-molecule oncology drugs have been approved by the FDA.
Because of the inherent heterogeneity of tumors, these small molecules are often …

Combinatorial CRISPR-Cas screens have advanced the mapping of genetic interactions,
but their experimental scale limits the number of targetable gene combinations. Here, we …

Cellular systems show a wide range of signaling dynamics. Many of these dynamics are
highly stereotyped, such as oscillations at a fixed frequency. However, most studies looking …

Focal adhesion kinase (FAK) and Wnt signaling pathways are important contributors to
tumorigenesis in several cancers. While most results come from studies investigating these …

Cell-autonomous changes in p53 expression govern the duration and outcome of cell-cycle
arrest at the G2 checkpoint for DNA damage. Here, we report that mitogen-activated protein …

Cancer is a complex disease whereby multiple genetic aberrations, epigenetic
modifications, metabolic reprogramming, and the microenvironment contribute to the …

Overexpression of drug efflux transporters is commonly associated with multidrug-resistance
in cancer therapy. Here for the first time, we investigated the ability of diindolylmethane …

Apoptosis is a tightly controlled, coordinated cellular event responsible for inducing
programmed cell death to rid the body of defective or unfit cells. Inhibition of apoptosis is …